Navigation Links
Current Trends for Conducting Clinical Trials in China, New Life Science Webinar Hosted By Xtalks
Date:11/4/2013

Toronto, Canada (PRWEB) November 04, 2013

With steadily increasing drug development costs and timelines and the desire to access global patient populations, conducting clinical trials in Asian countries has rapidly become an appealing option for many pharmaceutical companies. However, conducting studies in these countries requires very careful planning to succeed. Accessing global patient populations in emerging markets requires a firm understanding of how to approach differences in culture, language, business practices, and regulatory frameworks. Furthermore, recent trends in population dynamics and diseases and their impact on healthcare have been shaping the future of clinical trials in Asia and particularly in China.

In this webinar, an overview of the market environment along with the key operational, logistical, and regulatory aspects of conducting clinical trials in China and other Asian countries will be discussed by Dr. Patrice Hugo, Chief Scientist for Scientific Affairs at LabCorp Clinical Trials, and Dr. Li Yan, Executive Director of Clinical Development for Infectious Diseases, Oncology, Respiratory & Immunology, and Vaccines in Emerging Markets at Merck.

Key highlights:

  •     Why Asia and China are good opportunities for clinical trials?
  •     Advantages and challenges of conducting trials in the region
  •     Recent trends in emerging diseases and their impact on healthcare in China
  •     Opportunities around unmet medical needs
  •     Leveraging regulatory and clinical trial networks to expedite drug development by focusing on locally relevant diseases
  •     Private-public partnerships
  •     Evolving hurdles and opportunities – including regulatory, pharmacodynamics/biomarkers, clinical/medical challenges, and inherited genetic differences in patient population
  •     Lessons learned from conducting clinical trials in China, a central laboratory’s perspective

For more information about this event or to register, visit: http://xtalks.com/Conducting-Clinical-Trials-in-China.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11281644.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Great E2 Hand Soap Challenge Asks Food Processors and Food Handlers: How Good is the E2 Hand Soap You’re Currently Using?
2. BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004)
3. Biotechnology Reagents Market by Technology, Applications and End-Users - Current Trends, Opportunities and Global Forecasts to 2016
4. Currently approved drugs found effective in laboratory mice against bioterror threats
5. Life Technologies to Invest $18 Million in Facility Expansion and Current Good Manufacturing Practice Compliance Plan
6. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
7. CfPIE’s Newest Training Course Facilitates Life Science Professionals in Staying Current with FDA Approval Trends
8. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
9. Electronics without current: Finnish team to research the future of nanoelectronics
10. Tri-Valley Dentist Dr. Endre Selmeczy Currently Features Oral Sedation Dentistry
11. Novocure Announces Launch of Recurrent Glioblastoma Product Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery ... announced today the appointment of a new Chairman, Mr ... Carmine , effective immediately. James Garner , ... Executive Director and former Acting CEO, Mr Iain Ross ... Non-Executive Director. --> James Garner , has also ...
(Date:2/4/2016)... ... 04, 2016 , ... Shimadzu Scientific Instruments will showcase several ... and poster sessions, and present on the analysis of mycotoxins and medical cannabis ... to 10 at the Georgia World Congress Center in Atlanta, Georgia. , ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
Breaking Biology Technology:
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/7/2016)... -- Various factors have contributed to the rise ... and biosimilars. Some of these factors include the ... for cost-effective alternatives, growing burden of chronic diseases, ... of their corresponding patented biologic drugs, and are ... efficacy. The global biosimilars market is estimated to ...
Breaking Biology News(10 mins):